Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Tinengotinib
DRUG
3 trials
Sponsors
TransThera Sciences (Nanjing), Inc.
, Memorial Sloan Kettering Cancer Center
Conditions
Advanced Solid Tumors
Breast Cancer
Cholangiocarcinoma
Prostate Cancer
Phase 1
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Recruiting
NCT06457919
Memorial Sloan Kettering Cancer Center
Prostate Cancer
Start: 2024-06-04
End: 2027-06-01
Target: 50
Updated: 2026-06-25
Phase 2
Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
Recruiting
NCT07498478
TransThera Sciences (Nanjing), Inc.
Breast Cancer
Start: 2026-03-17
End: 2027-12-31
Target: 94
Updated: 2026-03-27
Unknown Phase
Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors
NCT06370013
TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumors, Cholangiocarcinoma
Updated: 2024-04-17
Related Papers
A phase 1b/2 study evaluating the activity of tinengotinib in combination with androgen receptor pathway inhibitors (ARPIs) in patients with metastatic castration resistant prostate cancer (mCRPC).
Journal of Clinical Oncology
2025-02-10